Physician profile
Muhammad A Idrees
NPI 1912960774
$1,424.67
in general payments reported to CMS, 2019-2025
15 companies · $17.17 in 2025
The $17.17 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2021: $231 · 2022: $287 · 2023: $299 · 2024: $425 · 2025: $17.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $836.57 | 2021-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $104.69 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $74.84 | 2021 | |
| Glaxosmithkline, LLC. | $61.30 | 2019-2022 | |
| Abbvie INC. | $59.17 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.16 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $56.61 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaqta |
| Janssen Pharmaceuticals, INC | $36.31 | 2019-2022 | |
| Pfizer INC. | $27.34 | 2019 | |
| Abbott Laboratories | $22.44 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $20.75 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.79 | 2022 | |
| Seqirus USA INC | $17.17 | 2025 | Flucelvax, Fluad |
| Phadia US INC. | $15.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Idrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.